Pharma BD Deal Intelligence
Eli Lilly and Company / CSL Limited
2026 · Licensing/Option · $100M · Complete
CSL granted Eli Lilly an exclusive license to its anti-interleukin-6 monoclonal antibody clazakizumab for indications other than the prevention of cardiovascular events in end-stage kidney disease, which CSL retains. CSL receives US$100 million upfront and is eligible for undisclosed clinical, regulatory and commercial milestone payments plus royalties on global net sales. Clazakizumab had previously missed the primary endpoint of a Phase III organ-transplant study.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.
Key facts
- Announced Feb 18, 2026
- Deal value $100M
- Deal type Licensing/Option
- Therapeutic area Immunology, Nephrology, Cardiovascular
- Indications Indications outside prevention of cardiovascular events in end-stage kidney disease (Lilly rights)
- Key assets Clazakizumab, a Phase III-stage anti-IL-6 monoclonal antibody
- Mechanism Anti-interleukin-6 (IL-6) monoclonal antibody
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · Eli Lilly and Company deals · Immunology deals